P252 a device for facilitated subcutaneous immunoglobulin using patient-centric design and modular innovation principles

Immune Globulin Infusion (IGI) 10% (Human) facilitated with Recombinant Human Hyaluronidase (rHuPH20; fSCIG) is approved for treatment of primary and secondary immunodeficiency diseases (PID and SID) in Europe, and for adult patients with PID in the United States. For fSCIG administration, rHuPH20 is infused before immunoglobulin administration. rHuPH20 and immunoglobulin G (IgG) are co-packaged in dual-vial units (DVUs) to ensure correct ratios of the drugs are administered.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research